Abstract #0148

Targeted Use of 1H-MRS Is as Accurate as Histology in the Diagnosis of Glioblastoma Multiforme.

Greg Fellows¹, Alan James Wright², Naomi Sibtain³, Philip Rich⁴, Kirstie S. Opstad², Dominick J.O McIntyre⁵, Brian Anthony Bell¹, John Griffiths⁵, Franklyn Arron Howe⁶

¹Academic Neurosurgery Unit, St. George's University of London, London, UK; ²Basic Medical Sciences, St. George's University of London, London, UK; ³Neuroradiology, Kings College Hospital NHS Trust, London, UK; ⁴Neuroradiology, St. George's Hospital NHS Trust, London, UK; ⁵CRUK Cambridge Research Institute, Cambridge, UK; ⁶Cardiac and Vascular Sciences, St. George's University of London, London, UK

Oncological practice requires histopathological confirmation of glioblastoma multiforme (GBM) prior to radiotherapy. If lesion location or patient health precludes surgical debulking prior to treatment, then 1H MRS could provide a clinically useful alternative diagnosis to biopsy. 89 patients with 1H-MRS, CT and MRI were evaluated neuroradiologically and spectroscopically. Of patients selected on clinical and neuroradiological grounds for diagnostic biopsy alone, there was 100% concordance between a spectroscopy and histopathological diagnosis of GBM. We propose a 1H MRS protocol for accurate diagnosis of a subset of GBM patients for which a surgical procedure and treatment delay could be avoided.